Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00777231 | Phase I/II Pilot Study of Mixed Chimerism to Treat Hemoglobinopathies | PHASE1 | COMPLETED | 9 | — | — | Jan 1, 2005 | Aug 1, 2013 | Oct 14, 2020 | 3 | United States |
Tests are done at key time points to monitor for donor chimerism by evaluating presence of bone marrow-derived hematopoietic stem cells.
| Arm | Type | Description |
|---|---|---|
| Sickle Cell Disease | EXPERIMENTAL | Recipients treated with an enriched hematopoetic stem cell infusion |
| Non-Malignant Disorders | EXPERIMENTAL | Recipients treated with an enriched hematopoetic stem cell infusion |
| Aplastic Anemia | EXPERIMENTAL | Recipients treated with an enriched hematopoetic stem cell infusion |
| Sickle Cell Disease : Extended Protocol | EXPERIMENTAL | Recipients treated with an enriched hematopoetic stem cell infusion and Campath 1H conditioning |
| Name | Type | Description |
|---|---|---|
| Enriched Hematopoetic Stem Cell Infusion | BIOLOGICAL | Enriched Hematopoetic Stem Cell Infusion |
Inclusion Criteria: The following criteria are established to identify subjects with sickle cell disease (SCD) who have a high predicted morbidity and are at risk for early mortality. Subjects with S/S disease, S/C disease, Hemoglobin H disease, Alpha Thalassemia Major, Thalassemia Major (also know...